Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.33
+0.35 (7.03%)
At close: Mar 6, 2026, 4:00 PM EST
5.35
+0.02 (0.41%)
After-hours: Mar 6, 2026, 5:14 PM EST
Immuneering Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | - | 0.32 | 2.08 | |
| Revenue Growth (YoY) | - | - | - | -84.76% | -10.02% | |
| Cost of Revenue | - | - | - | 0.16 | 1.15 | |
| Gross Profit | - | - | - | 0.16 | 0.93 | |
| Selling, General & Admin | 17.3 | 16.08 | 16.76 | 15.61 | 8.27 | |
| Research & Development | 42.05 | 47.96 | 41.62 | 36.27 | 26.54 | |
| Amortization of Goodwill & Intangibles | 0.03 | 0.03 | 0.03 | 0.03 | - | |
| Operating Expenses | 59.38 | 64.07 | 58.41 | 51.9 | 34.81 | |
| Operating Income | -59.38 | -64.07 | -58.41 | -51.74 | -33.89 | |
| Interest & Investment Income | 3.04 | 2.59 | 3.61 | 1.01 | 0.17 | |
| Other Non Operating Income (Expenses) | 0.31 | 0.18 | 0.32 | 0.05 | 0 | |
| EBT Excluding Unusual Items | -56.02 | -61.3 | -54.49 | -50.68 | -33.71 | |
| Gain (Loss) on Sale of Investments | - | 0.26 | 1.02 | 0.17 | -0.13 | |
| Pretax Income | -56.02 | -61.04 | -53.47 | -50.51 | -33.84 | |
| Income Tax Expense | - | - | - | - | -0.31 | |
| Net Income | -56.02 | -61.04 | -53.47 | -50.51 | -33.54 | |
| Net Income to Common | -56.02 | -61.04 | -53.47 | -50.51 | -33.54 | |
| Shares Outstanding (Basic) | 44 | 30 | 28 | 26 | 14 | |
| Shares Outstanding (Diluted) | 44 | 30 | 28 | 26 | 14 | |
| Shares Change (YoY) | 46.80% | 5.51% | 7.69% | 93.84% | 175.00% | |
| EPS (Basic) | -1.27 | -2.04 | -1.88 | -1.91 | -2.46 | |
| EPS (Diluted) | -1.27 | -2.04 | -1.88 | -1.91 | -2.46 | |
| Free Cash Flow | -45.49 | -55.08 | -49.31 | -44.84 | -30.91 | |
| Free Cash Flow Per Share | -1.03 | -1.84 | -1.74 | -1.70 | -2.27 | |
| Gross Margin | - | - | - | 50.11% | 44.56% | |
| Operating Margin | - | - | - | -16325.77% | -1629.17% | |
| Profit Margin | - | - | - | -15937.29% | -1612.33% | |
| Free Cash Flow Margin | - | - | - | -14148.44% | -1486.17% | |
| EBITDA | -59.02 | -63.69 | -58.06 | -51.47 | -33.84 | |
| D&A For EBITDA | 0.35 | 0.39 | 0.35 | 0.28 | 0.05 | |
| EBIT | -59.38 | -64.07 | -58.41 | -51.74 | -33.89 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.